By Kathryn Calkins
Staff Writer

Running Phase II trials sufficiently large to be pivotal studies is not a bad strategy. But companies may find that they are better off telling no one that they could file for regulatory approval based on the results, even though that means giving up the stock appreciation in anticipation of good data.